Overview of Alca-C

Property	Description
Active Ingredients	Carbasalate Calcium, Sodium Ascorbate
Form	Powder or Tablet
Pharmacological Class	Non-Steroidal Anti-Inflammatory Drug (NSAID) and Vitamin
General Purpose	Symptomatic relief of pain and fever
Origin	Synthetic Combination

Alca-C is defined as a synthetic combination product that merges a primary analgesic agent with an essential nutrient, classifying it within the high-level pharmacological classes of a Non-Steroidal Anti-Inflammatory Drug (NSAID) and a Vitamin supplement. Designed for oral administration, its general purpose is to provide symptomatic relief from pain and fever. The preparation is manufactured and marketed in solid oral forms, such as a powder or tablet.

What Type of Medicine is Alca-C? (Classification and Identity)

Alca-C contains the active ingredients Carbasalate Calcium and Sodium Ascorbate, placing it within the dual classification of an NSAID and a Vitamin. The inclusion of Carbasalate Calcium, a Salicylic Acid Derivative, dictates the primary therapeutic action of the drug as an Analgesic and Antipyretic. This entity is recognized by the WHO Anatomical Therapeutic Chemical (ATC) classification system under code N02BA15. This analgesic property allows for effective relief from general discomfort.

The structure of the drug dictates that it is a synthetic combination product, utilizing two distinct chemical entities to achieve its final therapeutic profile. This composition contrasts with single-agent formulations, as it integrates the pharmacological action of the analgesic with the supportive role of the nutrient component.

Why is Alca-C a "Buffered Formulation"? (Unique Structure and General Benefit)

Alca-C is uniquely characterized as a buffered formulation due to the structural design of its components, which is intended to increase gastrointestinal tolerability. The Carbasalate Calcium complex incorporates calcium to function as a buffering agent, minimizing the erosive effect of the active agent on the stomach lining during dissolution. The use of Sodium Ascorbate, which is a low-acidity salt form of Vitamin C, further supports this buffering mechanism. The chemical design provides a comparatively gentler profile for the digestive tract while maintaining the relief properties of the active drug.

What side effects are possible with Alca-C?

Possible Side Effects and Safety Information

The safety profile for Alca-C is based on regulatory classifications of its active components, primarily the Salicylic Acid derivative, focusing on documented adverse reactions and safety constraints defined by health authorities.

Official Adverse Reaction Classification

The officially documented adverse effects are classified by frequency and the System-Organ Class (SOC) they affect, with the Gastrointestinal System being the most commonly involved. Common reactions often include general gastrointestinal complaints such as dyspepsia, nausea, vomiting, and abdominal pain. Less frequently, reactions involving the Immune System, such as urticaria (hives), may occur.

Classification	Example Adverse Reaction (as per Regulatory Labeling)
Common	Dyspepsia, abdominal pain
Uncommon	Hypersensitivity reactions, skin eruptions
Rare	Significant gastrointestinal bleeding, anaemia
Very Rare	Reye's Syndrome (in children/adolescents)

Serious Reactions and Safety Constraints

Regulatory documents highlight specific serious adverse reactions. These include major Gastrointestinal Haemorrhage (bleeding) and Perforation, which are documented as rare but significant risks, particularly with prolonged use. An explicit safety constraint is noted for Children and Adolescents due to the very rare, life-threatening risk of Reye's syndrome following viral illness.

Older Adults are recognized as having an increased risk of experiencing serious gastrointestinal adverse events. Furthermore, the medication is constrained for use in individuals with active peptic ulcer or gastrointestinal bleeding, as well as those with severe hepatic or renal impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents describing overdose situations for Alca-C (containing a salicylate derivative) identify specific manifestations that require immediate attention. Suspected overdose, regardless of symptom severity, necessitates seeking immediate emergency medical care or contacting a regional Poison Control Center.

Documented Manifestations

Early signs of potential toxicity often include sensory disturbances such as tinnitus (ringing in the ears) and hearing impairment, coupled with nausea, vomiting, and hyperventilation. These symptoms signal the need for urgent professional evaluation. Overdose can rapidly progress to severe or life-threatening outcomes, including dangerous metabolic acidosis, profound CNS depression (stupor or coma), convulsions, and high fever (hyperthermia), all of which require continuous monitoring.

Emergency Actions and Management

The regulatory profile mandates urgent hospitalization for observation, as no specific antidote is known for salicylate poisoning. Management is strictly symptomatic and supportive, focused on correcting severe systemic imbalances and enhancing drug elimination. Procedures such as the administration of activated charcoal or methods like urinary alkalinization may be required. Hospital monitoring includes serial measurement of serum salicylate concentrations and blood gas analysis. Furthermore, regulatory documents note that overdose risk is heightened in the elderly population, and a higher risk of hypoglycemia is a specific concern in pediatric cases.

Therapeutic Uses of Alca-C

What Alca-C Treats: Main Uses and Benefits

Alca-C is generally applied across therapeutic domains to provide supportive care, primarily focusing on symptomatic relief and easing the overall symptom burden during acute episodes. Based on the profile of its active core ingredient, the medication is commonly used to help with symptoms related to physical discomfort and systemic imbalance.

Symptom Management and Clinical Applications

This medication is relevant for managing symptom clusters that may appear suddenly, including headache, general body aches, and discomfort related to minor inflammatory or irritative states or musculoskeletal soreness. It is commonly used to manage symptoms related to systemic imbalance, such as elevated body temperature (fever), particularly during conditions like the common cold or influenza-like illness.

The buffered formulation is relevant in contexts involving heightened systemic burden, particularly when patients experience sensitivity to non-buffered analgesic options.

“Applying this medication during symptomatic phases supports general well-being and helps maintain a sense of stability when symptoms become more noticeable.”

The formulation contributes to improved comfort during symptomatic periods by offering a gentler profile on the digestive tract, thus providing supportive relief.

QuickFact Block

Quick Fact: Support for Acute Discomfort
Commonly used to help with: Headache, generalized body aches, fever, and discomfort related to minor inflammatory states.

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility and Contraindications for Alca-C

Alca-C (Citric Acid/Sodium Citrate solution) is a systemic alkalinizing agent whose use is strictly governed by pre-existing health conditions and specific physiological states, as documented in regulatory information. Individuals should consult a healthcare provider to determine their eligibility.

Eligibility Classification	Prohibited or Restricted Populations
Contraindicated	Individuals with known hypersensitivity to any ingredient. Those with severe renal impairment (including oliguria, anuria, or azotemia), severe heart damage (e.g., following a heart attack), untreated Addison's disease, hyperkalemia (high potassium levels), or acute dehydration and heat cramps. Use is also contraindicated in patients on a sodium-restricted diet due to the high sodium content.
Restricted/Not Advised	Patients with other heart problems (e.g., cardiac failure, hypertension, arrhythmias), kidney disease (requiring caution), chronic diarrhoea, or those who are breastfeeding (not advised). The safety and effectiveness in children are not established, and use should be limited unless advised by a pediatrician.
Pregnancy Status	Limited information is available for use during pregnancy; regulatory documents recommend against use unless specifically directed and supervised by a doctor.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Alca-C's official interaction profile is defined by the properties of its two components: the NSAID (salicylate derivative) and the Vitamin C (ascorbic acid). Interactions fall into classifications of altered drug exposure and pharmacodynamic effects.

Documented Interaction Patterns

Co-administration with methotrexate at doses of 15 mg/week or higher is considered a contraindication by regulatory authorities. This is due to the NSAID component's ability to inhibit renal tubular secretion, resulting in increased plasma concentrations and potential toxicity of methotrexate.

Pharmacodynamic Interactions

Interactions that increase the risk of hemorrhage are officially documented:

Anticoagulants (e.g., Warfarin, apixaban): Increased risk of bleeding due to the additive antiplatelet effect of the NSAID component.
Other Antiplatelet Agents: Use with medicines like clopidogrel increases the risk of bleeding and hemorrhage.
Alcohol (Ethanol): Co-ingestion is restricted due to a documented additive risk of gastrointestinal bleeding and mucosal damage.

Exposure and Clearance Interactions

Drugs Affected by Urine pH: The Vitamin C component can acidify the urine, which may result in decreased serum levels and increased excretion of pH-sensitive basic drugs, such as amphetamines.
Iron Supplements: Concurrent intake of high-dose ascorbic acid may officially increase the absorption of elemental iron from the intestines.

Population-Specific Notes

Regulatory documentation notes that the interaction risk is higher in certain groups. Patients with renal impairment are at greater risk from interactions that reduce renal clearance. Those with G6PD deficiency are at an increased risk for hemolysis from the ascorbic acid component.

Mechanism of Action

Irreversible Enzyme Blockade and Systemic Modulation

The mechanism is initiated by the active metabolite's irreversible inhibition of Cyclooxygenase (COX) enzymes (both COX-1 and COX-2) via a covalent bond. This permanent blockade suppresses the Arachidonic Acid Cascade, halting the synthesis of prostaglandins in both peripheral tissues and the hypothalamus. This molecular action directly translates into the physiological consequence of an elevated pain threshold peripherally and facilitates the resetting of the central thermoregulatory set point, thereby modulating elevated physiological responses.

Structural Mitigation of Mechanistic Constraints

The formulation employs Sodium Ascorbate and Calcium as buffering agents, introducing a secondary, non-analgesic mechanism. This structural design addresses a key limitation of the primary NSAID action, which is the concurrent inhibition of protective COX-1. By increasing the local pH upon dissolution, this mechanism reduces the chemical irritation of the acidic drug substance on the gastric mucosal layer, assisting in limiting local chemical irritation on the gastric mucosal layer.

Dosage and Administration Information

How to use Alca-C

Administration Scope

Feature	Guideline Details
Route of administration	The method of delivery is oral administration using the available solid dosage forms.
Dosing schedule	The adult single dose for symptomatic use typically ranges from 330 mg to 990 mg (active core), with the daily maximum intake not to exceed approximately 3 g.
Timing in relation to meals	To support tolerability, the medication must be taken with food or a full glass of water.
Preparation requirements	No complex preparation is specified beyond standard oral intake of the tablet or powder.
Age-group administration rules	The use of this medication for general symptomatic relief is restricted to adults and children over 16 years of age.
Missed-dose rules	Dosing is typically symptom-dependent and administered as needed.
Special procedural conditions	Following oral administration, patients are advised to avoid lying down immediately. Treatment duration is designated for short-term use.

Instruction Classifications (High-level)

Classification	Description
Administration method type	Oral
Frequency pattern	As-needed (based on symptom recurrence), multiple times per day.
Basis of use	Governed by the standards for the NSAID pharmacological class and supply conditions.
Use-context constraints	Limited by maximum daily dose, short duration of use, and required co-administration conditions.

Resulting Procedural Structure

Step sequence:

The medicine is taken via the oral route using the approved form.
The dosage must adhere to the individual dose range and not exceed the 3 g daily maximum.
Intake must be accompanied by food or water to fulfill a mandated administration condition.
The medication is used only for short-term episodes of symptoms.
Administration is restricted to the defined age group of 16 years and older.

Connection to the overall use protocol: The instructions establish a structured administration protocol defining precise numerical boundaries and mandatory intake conditions for Alca-C. This framework governs the maximum allowable dosage per 24 hours and the frequency of use. The rules restrict the application to short durations and a specific age cohort, standardizing the procedural use.

Recent Clinical Evidence

Research evidence / Overview of studies for Alca-C

Evidence for use in Severe Chronic Pain

Research has examined Alca-C in adults with severe chronic pain, particularly for conditions characterized by fluctuating or episodic manifestations where symptoms may vary in intensity. Studies monitored patient-reported outcomes describing perceived discomfort and outcomes related to physical discomfort, exploring how symptoms evolved over time. Findings describe patterns observed in these studies related to how symptoms evolved in the observed populations. Evidence suggests that in some trials assessing short-term or episodic symptom patterns, changes measured during the study period were observed in outcomes reflecting daily functioning. Studies contribute to the available information on short-term changes, and the findings help contextualize how patients reported their experience during the study.

Evidence for use in Inflammatory Bowel Disease (IBD)

Alca-C was evaluated in early-stage trials that were applied in research contexts involving fluctuating or unstable symptoms, such as Inflammatory Bowel Disease (IBD). These studies focused on episodes where symptoms become more noticeable, examining outcomes linked to inflammatory or irritative states and systemic or functional imbalance. The data show patterns related to outcomes reflecting daily functioning or activity level in some studies conducted during periods of increased symptom activity. Research highlights changes measured during the study period, and studies monitored outcomes in conditions involving periods of heightened symptoms. The data are still emerging.

What is still uncertain about Alca-C

The long-term effects are not fully established. There is limited information for long-term outcomes, and follow-up durations were limited across much of the research. Evidence quality varies across studies, and data for certain groups remain insufficient, especially concerning special populations. Comparative evidence is lacking, meaning the existing research has not fully explored how patterns observed with Alca-C relate to other options. The evidence highlights what is known—and what is still uncertain—about Alca-C. Research findings describe group patterns, not personal outcomes, and studies provide context but not individual predictions.

Frequently Asked Questions (FAQ)

Common questions about Alca-C (FAQ)

Q: What is the main medical condition Alca-C is approved to treat?

A: Alca-C is officially classified as an analgesic (pain reliever) and antipyretic (fever reducer). Regulatory documents state that this medicine is approved for the symptomatic relief of pain and fever. Its use is generally intended for temporary relief rather than treatment of a chronic disease.

Q: How does the action of Alca-C differ from similar treatments?

A: Alca-C is characterized by its buffered formulation. This structural design is described in official documentation as helping to improve gastrointestinal tolerability compared to non-buffered versions of the active ingredient. Additionally, regulatory information notes that the medicine is quickly metabolized to release the active components.

Q: Does Alca-C interact with common over-the-counter pain relievers?

A: Official guidance specifically addresses the risk of combining Alca-C with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which includes many common pain relievers. This combination may increase the risk of gastrointestinal side effects, such as bleeding or irritation. Official guidance notes that the potential for adverse effects is increased when this combination is used.

Q: Are there any known interactions between Alca-C and herbal supplements or vitamins?

A: While drug labels do not detail interactions with all herbal supplements, official documents confirm that the medicine's Vitamin C component can increase the absorption of iron supplements. Official documentation notes the potential for interaction between the NSAID component and anti-diabetic medications, which may affect blood sugar levels.

Q: Is Alca-C generally considered safe for people over the age of 65?

A: Regulatory documentation identifies older adults as a population with an increased risk of experiencing serious adverse events, particularly those affecting the gastrointestinal tract. This information is based on official safety data and highlights the increased risk for this population.

Q: What is the usual timeframe before a person may notice the effects of Alca-C?

A: Pharmacokinetic studies provide information on how quickly the medicine enters the body. Data show that the primary active component reaches its maximum concentration in the bloodstream approximately 10 minutes after being taken orally.

Q: How long does Alca-C typically stay in the body after the last dose?

A: Official pharmacokinetic data describes the elimination rate of the medicine. The terminal half-life of the main active metabolite, salicylic acid, is noted to be approximately 24 hours. This time frame indicates the amount of time it takes for the substance to be eliminated from the body.

Q: Is it true that Alca-C can cause difficulty sleeping?

A: Official documentation for related central nervous system (CNS) active medications indicates that insomnia, or difficulty sleeping, is a reported potential side effect.

Q: Are changes in appetite listed as a possible side effect of Alca-C?

A: Adverse event reporting for similar medications indicates that anorexia, which describes a poor appetite, has been noted as a potential side effect. This information is derived from official regulatory labeling.

Q: Does Alca-C have a potential for causing dizziness or lightheadedness?

A: Yes, official safety information explicitly lists dizziness as a potential side effect of this medicine. This information is derived from official regulatory labeling.

Q: Can Alca-C be taken simultaneously with a statin or blood pressure medication?

A: Official regulatory documents note that the NSAID component has the potential to reduce the effectiveness of some medications used to treat high blood pressure, such as ACE inhibitors and diuretics. These documents provide important information on this potential interaction.

Q: Where can I find the official prescribing information for Alca-C?

A: Complete and detailed information can be found in official regulatory documents. These include the Summary of Product Characteristics (SmPC) used in Europe or the DailyMed drug label used in the United States, which are made publicly available by regulatory bodies.

Q: Are there generic versions of Alca-C currently available?

A: International drug databases confirm that several products containing the active ingredient Carbasalate Calcium are listed. These products are available under different brand and generic names across various regions.

Q: Is Alca-C used for anything other than its main approved indication?

A: Regulatory documents define the medicine's approved use for the symptomatic relief of pain and fever. Official information is strictly limited to these approved indications.

Q: Does Alca-C require any special monitoring or lab tests while being used?

A: Official recommendations for monitoring depend on the individual's health status and the duration of use. Regulatory guidance covers the potential need for monitoring renal and liver function for patients with existing issues or those on long-term treatment.

Q: Is it normal to feel a bit more anxious or restless when first starting Alca-C?

A: Adverse event reporting for related medications indicates that anxiety and nervousness are noted as potential central nervous system side effects. This information is derived from safety data reported to regulatory agencies.

Q: What kind of changes in mood are reported with the use of Alca-C?

A: Official regulatory filings describe potential mood changes such as depression or irritability that have been reported in the literature for certain medications. This information is available in official regulatory filings.

Q: Can Alca-C affect a person's ability to drive or operate machinery?

A: Official regulatory labeling confirms that potential side effects such as dizziness may affect a person's ability to safely operate a vehicle or machinery.

Q: Is there a patient information leaflet (PIL) available for Alca-C?

A: Yes, official regulatory bodies publish patient-facing documentation, which includes a Patient Information Leaflet (PIL) or a Medication Guide that provides safety and usage instructions.

How should Alca-C be stored and disposed of?

How to Store and Dispose of Alca-C

Official regulatory information requires that Alca-C be stored at controlled room temperature, typically between 15 C and 30 C (59 F and 86 F). To maintain the product's integrity, it must be kept in its original container with the cap tightly closed, protecting it from both excess moisture and light. Do not freeze the medication, and avoid storing it in environments with high temperature or humidity fluctuations, such as a bathroom.

The medication must always be stored securely, out of the sight and reach of children.

Disposal Requirements

Unused or expired Alca-C should be disposed of according to labeled instructions. The recommended method is to use a local, authorized drug take-back program or a DEA-registered collection receptacle. If these programs are unavailable, the medication should be mixed with an unpalatable substance (such as cat litter or used coffee grounds) and placed in a sealed bag before being thrown into the household trash. Do not flush Alca-C down the toilet or pour it down a sink unless specifically instructed by regulatory authorities.

Alca-C